Trial · NCT03310580

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

NCT03310580, Phase 2, Completed, Aerie Pharmaceuticals; results first posted 2019-11-15

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension. Trials, record NCT03310580. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03310580

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension
NCT number: NCT03310580
Status: Completed
Phases: Phase 2
Enrollment: 42 participants, actual
Lead sponsor: Aerie Pharmaceuticals
Conditions: Primary Open Angle Glaucoma or Ocular Hypertension
Interventions: AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Placebo
First posted: 2017-10-16
Last updated: 2019-12-23
Results first posted: 2019-11-15

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Mean Diurnal IOP (Intraocular Pressure) (mmHg)	28 Days	Mean diurnal intraocular pressure (IOP) at week 4, measured by Goldman Applanation Tonometry (GAT).
Secondary	Extent of Exposure	28 Days	Exposure to study medication in days for all treatment groups

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Mean Diurnal IOP (Intraocular Pressure) (mmHg)	28 Days	Intent to treat (ITT) population	mmHg	MEAN
SECONDARY	Extent of Exposure	28 Days	Exposure to study medication in days for all treatment groups	Days	MEAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Mean Diurnal IOP (Intraocular Pressure) (mmHg)	AR-13324 Ophthalmic Solution 0.02%	14.35	Standard Error 0.549	mmHg
Mean Diurnal IOP (Intraocular Pressure) (mmHg)	AR-13324 Ophthalmic Solution 0.04%	14.33	Standard Error 0.567	mmHg
Mean Diurnal IOP (Intraocular Pressure) (mmHg)	Placebo Comparator	17.32	Standard Error 0.576	mmHg
Extent of Exposure	AR-13324 Ophthalmic Solution 0.02%	27.9	Standard Deviation 1.91	Days
Extent of Exposure	AR-13324 Ophthalmic Solution 0.04%	26.8	Standard Deviation 7.56	Days
Extent of Exposure	Placebo Comparator	27.4	Standard Deviation 2.23	Days

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	AR-13324 Ophthalmic Solution 0.02%	15
Overall Study	STARTED	AR-13324 Ophthalmic Solution 0.04%	15
Overall Study	STARTED	Placebo Comparator	12
Overall Study	COMPLETED	AR-13324 Ophthalmic Solution 0.02%	15
Overall Study	COMPLETED	AR-13324 Ophthalmic Solution 0.04%	14
Overall Study	COMPLETED	Placebo Comparator	12
Overall Study	NOT COMPLETED	AR-13324 Ophthalmic Solution 0.02%	0
Overall Study	NOT COMPLETED	AR-13324 Ophthalmic Solution 0.04%	1
Overall Study	NOT COMPLETED	Placebo Comparator	0

Source ClinicalTrials.gov

Adverse events33

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Conjunctival hyperaemia	Eye disorders	AR-13324 Ophthalmic Solution 0.02%	10	15	10
other	Conjunctival hyperaemia	Eye disorders	AR-13324 Ophthalmic Solution 0.04%	10	14	10
other	Conjunctival hyperaemia	Eye disorders	Placebo Comparator	0	12	0
other	Eye Pruritus	Eye disorders	AR-13324 Ophthalmic Solution 0.02%	0	15	0
other	Eye Pruritus	Eye disorders	AR-13324 Ophthalmic Solution 0.04%	2	14	2
other	Eye Pruritus	Eye disorders	Placebo Comparator	1	12	1
other	Conjunctival hemorrhage	Eye disorders	AR-13324 Ophthalmic Solution 0.02%	0	15	0
other	Conjunctival hemorrhage	Eye disorders	AR-13324 Ophthalmic Solution 0.04%	2	14	2
other	Conjunctival hemorrhage	Eye disorders	Placebo Comparator	0	12	0
other	Dry eye	Eye disorders	AR-13324 Ophthalmic Solution 0.02%	0	15	0

1 to 10 of 33Source ClinicalTrials.gov

See all 33 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	AR-13324 Ophthalmic Solution 0.02%	0	15
Total, all-cause mortality	AR-13324 Ophthalmic Solution 0.04%	0	14
Total, all-cause mortality	Placebo Comparator	0	12
Total, other adverse events	AR-13324 Ophthalmic Solution 0.02%	10	15
Total, other adverse events	AR-13324 Ophthalmic Solution 0.04%	11	14
Total, other adverse events	Placebo Comparator	3	12
Total, serious adverse events	AR-13324 Ophthalmic Solution 0.02%	0	15
Total, serious adverse events	AR-13324 Ophthalmic Solution 0.04%	0	14
Total, serious adverse events	Placebo Comparator	0	12

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03310580

GET https://conductscience.org/api/trials/v1/NCT03310580/events?page=2

API reference For AI assistants